Cargando…

What is the future of CCR5 antagonists in rheumatoid arthritis?

Fleishaker and colleagues reported on a double-blind placebo controlled clinical trial of a C-C chemokine-receptor type 5 (CCR5) antagonist, maraviroc, in rheumatoid arthritis (RA) patients with inadequate response to methotrexate, showing that it was ineffective. Two additional CCR5 antagonists, SC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takeuchi, Tsutomu, Kameda, Hideto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446428/ https://www.ncbi.nlm.nih.gov/pubmed/22494450 http://dx.doi.org/10.1186/ar3775

Ejemplares similares

Overview of biotherapy in rheumatoid arthritis (RA)
por: Takeuchi, Tsutomu, et al.
Publicado: (2012)

The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan
por: Yamaoka, Kunihiro, et al.
Publicado: (2021)

Fcγ receptor IIIb polymorphism and use of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis
por: Okuyama, Ayumi, et al.
Publicado: (2010)

Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE)
por: Kameda, Hideto, et al.
Publicado: (2021)

Cartilage evaluation by ultrasonography in patients with rheumatoid arthritis: a scoping review
por: Ogura, Takehisa, et al.
Publicado: (2023)

Why CCR2 and CCR5 Blockade Failed and Why CCR1 Blockade Might Still Be Effective in the Treatment of Rheumatoid Arthritis
por: Lebre, Maria C., et al.
Publicado: (2011)

Rheumatoid arthritis: what do MRI and ultrasound show
por: Sudoł-Szopińska, Iwona, et al.
Publicado: (2017)

Rheumatoid Arthritis and Malignancy: What Should We Do With DMARDs?
por: Jeon, Chan Hong
Publicado: (2022)

Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients—REACTION 52-week study
por: Takeuchi, Tsutomu, et al.
Publicado: (2011)

Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study)
por: Yamanaka, Hisashi, et al.
Publicado: (2010)

Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study
por: Nakamura, Seiji, et al.
Publicado: (2016)

Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study
por: Kameda, Hideto, et al.
Publicado: (2020)

Association of age with the non-achievement of clinical and functional remission in rheumatoid arthritis
por: Aoki, Tadashi, et al.
Publicado: (2020)

Lack of association between the chemokine receptor 5 polymorphism CCR5delta32 in rheumatoid arthritis and juvenile idiopathic arthritis
por: Lindner, Ewald, et al.
Publicado: (2007)

The Rheumatoid Arthritis Risk Variant CCR6DNP Regulates CCR6 via PARP-1
por: Li, Gang, et al.
Publicado: (2016)

Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2)
por: Tanaka, Yoshiya, et al.
Publicado: (2008)

Modulation of inflammatory pain in response to a CCR2/CCR5 antagonist in rodent model
por: Okamoto, Masayuki, et al.
Publicado: (2013)

Rheumatoid Arthritis
por: Melchiorre, Daniela, et al.
Publicado: (2013)

Platelet-Derived Growth Factor as a Therapeutic Target for Systemic Autoimmune Diseases
por: Kameda, Hideto, et al.
Publicado: (2007)

CCR5 and CXCR4 antagonist and agonist binding sites
por: Teintze, Martin, et al.
Publicado: (2006)

Evolution of coreceptor utilization to escape CCR5 antagonist therapy
por: Zhang, Jie, et al.
Publicado: (2016)

CCR5Δ32 variant and cardiovascular disease in patients with rheumatoid arthritis: a cohort study
por: Rodríguez-Rodríguez, Luis, et al.
Publicado: (2011)

Periodontal disease, Porphyromonas gingivalis, and rheumatoid arthritis: what triggers autoimmunity and clinical disease?
por: Scher, Jose U, et al.
Publicado: (2013)

Atherosclerosis in Rheumatoid Arthritis
por: González-Gay, Miguel A., et al.
Publicado: (2012)

Vasculogenesis in rheumatoid arthritis
por: Szekanecz, Zoltán, et al.
Publicado: (2010)

Biomarkers in Rheumatoid Arthritis
por: Goëb, Vincent, et al.
Publicado: (2014)

Rheumatoid Arthritis in Minorities
por: Anaya, Juan-Manuel, et al.
Publicado: (2013)

Fatigue in rheumatoid arthritis
por: Choy, Ernest H, et al.
Publicado: (2019)

Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis
por: Lefebvre, Eric, et al.
Publicado: (2016)

Pharmacokinetics, Safety, and CCR2/CCR5 Antagonist Activity of Cenicriviroc in Participants With Mild or Moderate Hepatic Impairment
por: Lefebvre, E, et al.
Publicado: (2016)

In silco analysis of carboxamide derivatives of piperidine as potential antagonists of CCR5
por: Harishchander, A, et al.
Publicado: (2014)

Maraviroc – A CCR5 Antagonist for the Treatment of HIV-1 Infection
por: Van Der Ryst, Elna
Publicado: (2015)

Decision-Making Strategy for the Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD)
por: Yamakawa, Hideaki, et al.
Publicado: (2021)

Expression of CCR3, SOX5 and LC3 in patients with elderly onset rheumatoid arthritis and the clinical significance
por: Wang, Jing, et al.
Publicado: (2017)

Rheumatoid Arthritis and Vascular Failure - Rheumatoid Arthritis Is a Risk Factor for Cardiovascular Disease-
por: Oyama, Jun-ichi, et al.
Publicado: (2019)

Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study)
por: Takeuchi, Tsutomu, et al.
Publicado: (2011)

Nutrition and Diet in Rheumatoid Arthritis
por: Cutolo, Maurizio, et al.
Publicado: (2022)

Solid Cancers and Rheumatoid Arthritis
por: Kalliolias, George D., et al.
Publicado: (2023)

Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis
por: Puengel, Tobias, et al.
Publicado: (2022)

Association of the CCR5 gene with juvenile idiopathic arthritis
por: Hinks, A, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_6ompvkojr8jskkii5r7ct9dqid